Journal decision profile

Cancer Epidemiology Biomarkers & Prevention

Medicine

Cancer Epidemiology Biomarkers & Prevention's 2026 Journal Metrics Score is 0.8, ranking Q4 in Oncology and 1 other subfield. Two-year citation average from OpenAlex data, updated August 2026.

American Association for Cancer ResearchUnited StatespISSN 1055-9965eISSN 1538-7755
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
0.8

Journal Metrics Score 2026 · 2021–2024 window citedness 0.94.

Review & acceptance time
i
Review & acceptance timeCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
124 daysmedian

Middle 50%: 100–153 days

100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025

Cancer Epidemiology Biomarkers & Prevention accepts papers a median of 124 days after submission, including peer review and revisions. That is slower than 64% of comparable journals with PubMed timing data.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
Not available

No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.

Free preview · no sign-in

Does your manuscript fit Cancer Epidemiology Biomarkers & Prevention?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
0.82026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#20 / 1,143LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
6.1%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.82MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
124 daysIQR 100–153 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
743 / yr2021–2024 AVG
Field-normalized top 10% share6.1%

181 of 2,971 works · same type, year & subfield

Field-normalized top 1% share0.2%

7 works · same type, year & subfield

Median FWCI0.82×

Below field-year expectation

Source output rank#20

of 1,143 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.82, so its typical recent paper runs about 18% below its field benchmark.

What does Top 10% Share mean?

6.1% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

5402016
5922017
5142018
2742019
16822020
4312021
5822022
11942023
7642024
8642025

Recent work-type mix

2,971 OpenAlex works · 2021–2024

Conference abstract63.2%
Article35.6%
Review0.8%
Paratext0.1%
Editorial0.1%
Erratum0.1%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Cancer Epidemiology Biomarkers & Prevention publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Global Cancer Incidence and Screening349
Cervical Cancer and HPV Research190
Cardiovascular Health and Risk Factors157
Colorectal Cancer Screening and Detection99
Cancer Risks and Factors96
Economic and Financial Impacts of Cancer74
Childhood Cancer Survivors' Quality of Life59
Prostate Cancer Treatment and Research52
BRCA gene mutations in cancer51
Cancer Genomics and Diagnostics51
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 2,971 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
OncologyQ4
EpidemiologyQ4

Is Cancer Epidemiology Biomarkers & Prevention a good journal?

A lower-cited Q4 journal by citation data

By citation data, Cancer Epidemiology Biomarkers & Prevention is in the lowest quartile in Oncology and 1 other subfield and ranks #764 of 897 Oncology journals by Journal Metrics Score (top 86%). A Q4 placement means its papers are cited less than most in the subfield; on its own it does not mean the journal is predatory or that its peer review is weak. Cancer Epidemiology Biomarkers & Prevention's 2026 Journal Metrics Score is 0.8. Recent papers took a median of 124 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Oncology and Epidemiology, so check that your topic fits its scope.

Best quartile
Q4
Oncology
Rank in Oncology
#764 of 897
Top 86%
2026 Journal Metrics Score
0.8
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
124 days
Median, PubMed records
Papers published in 2025
864
OpenAlex works

Check before you submit

  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q4
Subfield Quartile
B3
CAS Block

Ranking and source check

#764
of 897 Oncology field journals
#15
among Q4 Oncology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
13,886
H-Index
212
Fully Open Access
No
Recent OA Works
5,263
Subject Areas
OncologyEpidemiology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Cancer Epidemiology Biomarkers & Prevention

  1. 1

    Check the scope

    OpenAlex classifies Cancer Epidemiology Biomarkers & Prevention's papers in subfields including Oncology and Epidemiology. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Cancer Epidemiology Biomarkers & Prevention homepage ↗
  3. 3

    Submit online

    Use the submit link in Cancer Epidemiology Biomarkers & Prevention's author guidelines; American Association for Cancer Research runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.

  4. 4

    Plan for costs

    OpenAlex has no article processing charge on record. Check the journal website for page charges or an optional open-access fee.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 124 days from submission to acceptance, including revisions (PubMed dates). Cancer Epidemiology Biomarkers & Prevention does not publish an acceptance rate.

New on PubMed

What's new in your field?

Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.

See a demo:GLP-1CRISPRLong COVID

Reviewer Two · coming soon

Know what reviewers will say before you submit to Cancer Epidemiology Biomarkers & Prevention

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Cancer Epidemiology Biomarkers & Prevention

Is Cancer Epidemiology Biomarkers & Prevention a good journal?

By citation data, Cancer Epidemiology Biomarkers & Prevention is in the lowest quartile in Oncology and 1 other subfield and ranks #764 of 897 Oncology journals by Journal Metrics Score (top 86%). A Q4 placement means its papers are cited less than most in the subfield; on its own it does not mean the journal is predatory or that its peer review is weak. Cancer Epidemiology Biomarkers & Prevention's 2026 Journal Metrics Score is 0.8. Recent papers took a median of 124 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Oncology and Epidemiology, so check that your topic fits its scope.

What is Cancer Epidemiology Biomarkers & Prevention's Journal Metrics Score in 2026?

Cancer Epidemiology Biomarkers & Prevention's 2026 Journal Metrics Score is 0.8, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Cancer Epidemiology Biomarkers & Prevention?

We have not found an official acceptance rate published by Cancer Epidemiology Biomarkers & Prevention or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 124 days from submission to acceptance. To judge selectivity, compare Cancer Epidemiology Biomarkers & Prevention's quartile and score with similar journals, or ask the editorial office.

What quartile is Cancer Epidemiology Biomarkers & Prevention in?

Cancer Epidemiology Biomarkers & Prevention's best quartile is Q4. By OpenAlex subfield: Q4 in Oncology; Q4 in Epidemiology. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Cancer Epidemiology Biomarkers & Prevention will not match this score exactly. Compare journals using one source at a time.

How long does Cancer Epidemiology Biomarkers & Prevention take to accept a paper?

Cancer Epidemiology Biomarkers & Prevention accepts papers a median of 124 days after submission across 100 recent PubMed records with both dates; the middle half took 100–153 days. This includes peer review, editorial handling, and revisions.

How long is the peer review time at Cancer Epidemiology Biomarkers & Prevention?

PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Cancer Epidemiology Biomarkers & Prevention, which includes peer review and revisions, has a median of 124 days. For the time to a first decision, check the journal's own website.

Is Cancer Epidemiology Biomarkers & Prevention faster than similar journals?

Cancer Epidemiology Biomarkers & Prevention's median of 124 days from submission to acceptance is slower than 64% of comparable journals with PubMed timing data.

Which journals are alternatives to Cancer Epidemiology Biomarkers & Prevention?

Comparable journals include Ca-A Cancer Journal For Clinicians, Jnci-Journal of the National Cancer Institute, Jnci Cancer Spectrum, and European Journal of Cancer Prevention. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Cancer Epidemiology Biomarkers & Prevention?

Submit online through the link in Cancer Epidemiology Biomarkers & Prevention's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 124 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search